Company: DARE
Filing Date: 2025-07-09
Form Type: 8-K
Source: 0001641172-25-018393
Chunk: 0

Company: Dare Bioscience, Inc.
Filing Date: 2025-07-09
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item      Departure                                                                                                                                 

As
reported in Item 5.07 below, at the 2025 annual meeting of stockholders of Daré Bioscience, Inc. (“ Daré,” “we,”
“us,” or “our”) (the “ Meeting”), our stockholders approved an amendment to the Daré Bioscience,
Inc. 2022 Stock Incentive Plan (the “2022 Plan Amendment”) to increase the number of shares available for issuance thereunder
by 600,000. Our board of directors previously approved the 2022 Plan Amendment, subject to and effective upon approval of the 2022 Plan
Amendment by our stockholders. A brief description of the terms and conditions of the 2022 Plan Amendment is in the section entitled
“ Proposal 4 - To Approve an Amendment to the Company’s 2022 Stock Incentive Plan” of the definitive proxy statement
for the Meeting filed with the U. S. Securities and Exchange Commission on April 24, 2025 (the “ Proxy Statement”), which description
is incorporated herein by reference. A copy of the 2022 Plan Amendment is filed as an exhibit to this report and incorporated by reference
herein.